M3258 is a highly potent, orally bioavailable, reversible, and selective inhibitor of the immunoproteasome subunit LMP7 (β5i), exhibiting strong antitumor activity in multiple myeloma xenograft models; it significantly and persistently inhibits LMP7 activity and ubiquitinated protein turnover in multiple myeloma cells, leading to the induction of apoptosis.